Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
about
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeksPhase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaTargeted Therapy of Ewing's Sarcoma.Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.Metabolism and transport of oxazaphosphorines and the clinical implications.Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancerLong-term nephrotoxicity in adult survivors of childhood cancer.Current treatment of soft tissue sarcomaThe role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes.Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells.Pharmacokinetic study of perioperative intravenous Ifosfamide.Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.Managing sarcoma: where have we come from and where are we going?Prenatal effects of transplacental exposure to ifosfamide in rats.Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy.Distribution of ifosfamide and metabolites between plasma and erythrocytes.Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.
P2860
Q33360843-54939E95-B410-4722-91EE-23FAFF988AABQ33417472-97FD2031-43C4-4750-A729-B4000070DF02Q34262377-531E0DE1-9224-410A-9EAC-AF13403419BEQ36154879-947C3695-C202-416E-9076-ABAB014C5AA1Q36360811-91959D71-0EFB-45A6-8C41-F94F7684581EQ36512499-4C9BBD1F-9511-44DC-AA9E-C1924A159AA4Q36536502-C79A65B2-C1F2-4758-8F16-5A46C8BA3A5FQ36616877-20E45F4C-857B-457D-AA60-4AF0ACA8C690Q36910939-E60FF3E2-8268-455E-B5C1-C3B3F035E750Q36935540-805A5DD5-514D-4E44-8B2B-0C1173BF8DA3Q36988710-E2DF1599-1A30-48DA-85E6-9A83A78E301AQ37038352-0AA298A4-ADFE-410E-8296-9B41B30D6F32Q40355100-0E2F648E-A87B-4214-92BE-79962E5FA3A7Q40583827-F4D72D72-2D17-4163-B75E-4268220B5979Q41050294-A0F8A3CC-DE23-452A-92B0-250C82AE1553Q41988197-8007F965-D500-41B0-94FC-037EFB07B076Q42492493-A79A5CFF-C0D3-45F8-B81B-BAD65E718B4AQ42961044-2841D1AC-5B7A-4CB8-918F-EFBC8D33AD51Q43824947-91F232B3-E501-4397-A25D-58CFD55BB0ECQ43880501-0AEE6322-7DA5-4CB2-82A5-0861D9EC2806Q46090646-B0E1D7C6-0C75-4E2B-A0F4-7C119FE28394Q46417406-DD2FF5A7-E4AA-4684-A768-A4F3ADF80E62Q52148939-9921F3F2-86F0-45B9-A0F8-3B5CFDFD5B04
P2860
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@ast
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@en
type
label
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@ast
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@en
prefLabel
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@ast
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@en
P2093
P1476
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
@en
P2093
Beijnen JH
Kerbusch T
Schellens JH
de Kraker J
van Putten JW
P356
10.2165/00003088-200140010-00004
P577
2001-01-01T00:00:00Z
P6179
1049217785